AtheroNova, Inc. is a development stage biotech company focused on discovering, researching, developing and licensing novel compounds designed to reduce or eliminate atherosclerotic plaque deposits. By reducing or eliminating atherosclerotic plaque deposits, the company would address the most lucrative segments of the multi-billion dollar prescription drug market: cardiology and stroke prevention.
Existing classes of atherosclerotic drugs, including statins, have demonstrated tremendous market success, rapidly achieving blockbuster status and billions of dollars in sales. However, statins, including the biggest blockbuster of all time, Lipitor, do not effectively reduce plaque. The enormous market success of statins is due to the fact that there are no competing options that directly reduce or eliminate plaque.
AtheroNova has acquired the intellectual property for a class of naturally occurring compounds that may significantly reduce the incidence and severity of atherosclerosis by preventing the formation of atherosclerotic plaques and dissolving existing plaques. The company currently has 22 patent pending applications and has received a freedom to operate opinion from McDermott Will & Emery LLP, one of the leading Intellectual Property firms in the world.
Let us hear your thoughts: AtheroNova Inc. Message Board